Dexcom Stock

Dexcom Revenue

The The revenue of Dexcom (DXCM) as of Aug 18, 2026 is 4.66 B USD. In the previous year, The revenue was 4.03 B USD — a change of 15.60% (higher).

Revenue

4.66 BUSD

YoY

15.60%

Last updated:

In 2026, Dexcom's sales reached 4.66 B USD, a 15.60% difference from the 4.03 B USD sales recorded in the previous year.

Revenue has compounded at 49.8% per year over the past 19 years to 4.66 B USD.

The Dexcom Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

REVENUE (B USD)
GROSS MARGIN (%)
Date
REVENUE (B USD)
GROSS MARGIN (%)
Jan 1, 2023
3.62 base
63.19 base
Jan 1, 2024
4.03 base
60.46 base
Jan 1, 2025
4.66 base
60.10 base
Jan 1, 2026 (e)
5.23 base
53.57 base
Jan 1, 2027 (e)
5.80 base
48.31 base
Jan 1, 2028 (e)
6.51 base
43.01 base
Jan 1, 2029 (e)
7.21 base
38.85 base
Jan 1, 2030 (e)
8.04 base
34.85 base
YEARREVENUE (B USD)GROSS MARGIN (%)
2030 est 8.0434.85
2029 est 7.2138.85
2028 est 6.5143.01
2027 est 5.8048.31
2026 est 5.2353.57
2025 4.6660.10
2024 4.0360.46
2023 3.6263.19
2022 2.9164.72
2021 2.4568.63
2020 1.9366.44
2019 1.4863.11
2018 1.0364.36
2017 0.7268.49
2016 0.5766.00
2015 0.4069.25
2014 0.2668.02
2013 0.1662.56
2012 0.1046.65
2011 0.0847.00
2010 0.0537.92
2009 0.0312.33
2008 0.01-56.20
2007 0.00-175.25
2006 0.00-405.07
Access this data via the Eulerpool API

Dexcom Revenue

Dexcom Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
3.62 B USD
597.70 M USD
541.50 M USD
Jan 1, 2024
4.03 B USD
600.00 M USD
576.20 M USD
Jan 1, 2025
4.66 B USD
911.80 M USD
836.30 M USD
Jan 1, 2026 (e)
5.23 B USD
1.88 B USD
1.04 B USD
Jan 1, 2027 (e)
5.80 B USD
2.10 B USD
1.22 B USD
Jan 1, 2028 (e)
6.51 B USD
2.35 B USD
1.44 B USD
Jan 1, 2029 (e)
7.21 B USD
2.60 B USD
1.66 B USD
Jan 1, 2030 (e)
8.04 B USD
2.89 B USD
1.94 B USD

Dexcom Margins

Dexcom stock margins

The Dexcom margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Dexcom. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Dexcom.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
63.19 %
16.50 %
14.95 %
Jan 1, 2024
60.46 %
14.88 %
14.29 %
Jan 1, 2025
60.10 %
19.56 %
17.94 %
Jan 1, 2026 (e)
60.10 %
35.96 %
19.85 %
Jan 1, 2027 (e)
60.10 %
36.13 %
21.01 %
Jan 1, 2028 (e)
60.10 %
36.00 %
22.10 %
Jan 1, 2029 (e)
60.10 %
36.00 %
22.97 %
Jan 1, 2030 (e)
60.10 %
36.00 %
24.18 %

Dexcom Stock analysis

What does Dexcom do? Dexcom Inc is a US medical technology company specializing in the development and manufacturing of medical devices for monitoring blood sugar levels in diabetes. The company was founded in 1999 by Scott Glenn and John Burd and is headquartered in San Diego, California. Dexcom's history began with the development of a continuous glucose sensor by Scott Glenn, who himself has Type 1 diabetes. In 2006, the company received approval from the US Food and Drug Administration (FDA) for its first continuous glucose sensor, which was marketed as the "Dexcom STS". Since then, the company has developed and launched numerous other products. Dexcom's business model is based on offering solutions to improve the quality of life for people with diabetes through the use of modern technology. The company primarily offers continuous glucose monitoring (CGM) systems, which continuously and in real-time monitor blood sugar levels to optimize insulin therapy and avoid hypoglycemia. Dexcom's goal is to make the daily management of diabetes easier and safer, and to improve the quality of life for those affected. Currently, Dexcom offers two CGM systems: the "Dexcom G6" and the "Dexcom G7". The G6 system has been on the market since 2018 and has been used by over one million people worldwide. It consists of three components: a sensor, a transmitter, and a receiver. The sensor is placed under the skin and continuously measures glucose levels in the tissue. The transmitter sends the measurements to the receiver, which displays the current blood sugar level to the patient. Another option is to connect the system to a smartphone app. The G7 system is still in development and is expected to be launched in 2021. It promises even easier handling and longer battery life. Dexcom has also formed partnerships with other companies, such as insulin pump manufacturers like Tandem Diabetes Care, to enable integration of CGM systems into these devices and enable automated insulin therapy. Currently, Dexcom employs over 3,800 people worldwide and operates in over 50 countries. The company has experienced strong growth in recent years and has steadily increased its revenues. In 2019, Dexcom's revenue was approximately $1.5 billion, representing a 43% increase from the previous year. Overall, Dexcom has established itself as a leading provider in the field of continuous glucose monitoring with its innovative products and focus on improving the quality of life for people with diabetes. The company has successfully made the daily lives of millions of individuals worldwide easier and has become an important partner in diabetes care. Dexcom is one of the most popular companies on Eulerpool.

Revenue Details

Understanding Dexcom's Sales Figures

The sales figures of Dexcom originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Dexcom’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Dexcom's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Dexcom’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Dexcom stock

The revenue of Dexcom is 4.66 B USD in 2026.

The revenue of Dexcom changed from 4.03 B USD to 4.66 B USD, representing a 15.60% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The revenue Dexcom since 2006 – with annual values, charts, and detailed analysis.

Revenue is the total value of all goods sold in a period. It is calculated by multiplying the quantity of each product sold by its selling price. Revenue does not include any costs (material costs, personnel costs, etc.), whereas net proceeds only deduct revenue reductions associated with the sale (discounts, etc.).

The revenue's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The revenue's Dexcom historically and in real time.

The revenue in assessing a stock

Revenue is an important financial measure used in the valuation of stocks. It is a measure of a company's economic activity and can serve as an indicator of the company's success. Revenue is considered one of the most important factors in stock valuation. In addition, revenue can also be used to calculate other financial measures such as earnings per share and price-earnings ratio.

History and utilization of revenue

Revenue has long been considered one of the most important financial indicators. It was used in the 19th century as one of the first financial indicators to measure a company's economic activity. Since then, revenue has been regularly used to evaluate companies.

Revenue is usually calculated as a percentage of the company's equity. It can also be used to determine the overall profitability of a company. There are many different types of revenue that can be used to measure a company's economic activity, such as gross revenue, net revenue, and revenue from international business.

The revenue can also be used to evaluate stocks. For example, the revenue of a company can be used to evaluate the success of the company. If a company has high revenue, it means that it is a profitable company because it has high demand for its products or services.

Calculation and Application of Revenue

In order to calculate a company's revenue, the company's income must be deducted from its expenses. The income can come from various sources, such as sales, licensing fees, services, etc. The expenses can include costs for production, procurement, inventory, sales, and administration.

The revenue can then be used to calculate various financial ratios. For example, the revenue can be used to calculate the price-earnings ratio (P/E ratio) of a company. This is a measure of a company's profitability, calculated by taking the ratio of the stock price to earnings per share.

Revenue can also be used to calculate earnings per share (EPS) of a company. This is a measure of a company's profit per share. EPS is calculated by dividing earnings by the number of shares issued.

Use of revenue by investors

Investors use revenue to evaluate stocks, as revenue is an indicator of a company's success. For example, an investor can compare a company's revenue to see how successful it is. An investor can also use a company's revenue to calculate its price-to-earnings ratio and earnings per share.

An example: An investor looks at a company that has a revenue of 25 million euros. He compares this revenue to that of the competitor, which has a revenue of 35 million euros. The investor can then see that the company with 25 million euros in revenue is less successful than the company with 35 million euros in revenue.

Advantages and Disadvantages of Revenue.

Revenue is a very useful tool for valuing stocks as it measures a company's economic activity. Revenue can also be used to calculate other financial ratios such as the price-earnings ratio and earnings per share.

However, one disadvantage is that revenue alone is not a meaningful indicator of a company's success. It is important to consider revenue in comparison to other financial metrics such as earnings per share and price-to-earnings ratio to get a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Dexcom

All Key Metrics — Dexcom